Jubilant Life
- All
- News
- Videos
-
India's Jubilant Signs Licensing Deal For US Pharma Firm Gilead's COVID-19 Drug
India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India.
-
Jubilant Life To Buy Triad Isotopes' Radio-Pharmacy Business, Shares Gain
Jubilant Life Sciences said Triad operates the second largest radio-pharmacy network in the US with more than 50 pharmacies.
-
Nearly 200 Stocks Hit 52-Week High On BSE
Among major gainers were IL&FS Transportation Networks, IOC, Jubilant Life Sciences, MMTC and MOIL, taking the total number of companies to have touched their one year peak to 192.
-
Jubilant Life Sciences Unit Signs US Deal, Shares Surge Over 10%
At day's high, Jubilant Life Sciences shares recorded gains of more than 13 per cent in two trading sessions.
-
Jubilant Life Sciences Announces Price Hike Of Up To 15%
Jubilant Life Sciences is engaged in pharmaceuticals, life science ingredients and drug discovery solutions.
-
Jubilant Life Seeks Shareholders' Nod To Raise Upto Rs 1,000 Crore
This approval to the board to raise the amount also stipulates that this could be done in one or more series/tranches during a period of one year from the date of passing the resolution, it added.
-
Jubilant Life Sciences Posts Nearly 15% Rise In Q2 Profit
Jubilant Life Sciences said its international revenues were at Rs 984 crore, contributing 69 per cent to the revenues for the quarter.
-
Jubilant Life Gets USFDA Nod For Urinary Incontinence Drug
Jubilant Life Sciences said it has received 6 approvals from the USFDA during the year.
-
Jubilant Life Sciences Arm Gets Australia TGA Nod For Lung Scan Drug
Jubilant Life Sciences on Tuesday said its wholly-owned subsidiary has received approval from the Australian health regulator Therapeutic Goods Administration (TGA) for Lyophilized kit for preparation of injection used for lungs scan.
-
Jubilant Life Shares Jump 10% As Arm Gets USFDA Nod For Drug
Shares of Jubilant Life Sciences on Monday surged 10 per cent after the company's wholly-owned subsidiary received approval from the US health regulator for a new drug in the US market.
-
Jubilant Pharma Raises $300 Million Via Bonds
Drug firm Jubilant Life Sciences today said its subsidiary Jubilant Pharma has raised $300 million (approx Rs 1,998 crore) through issuance of five-year bonds to mainly retire debts.
-
Jubilant Life Jumps 8% On USFDA Nod For Hypertension Tablets
Jubilant Life Sciences stock surged nearly 8 per cent after it received final approval from the US health regulator to sell tablets used in the treatment of hypertension in the American market.
-
Jubilant Life Gets USFDA Nod For Hypertension Tablets
Jubilant Life Sciences said it has received approval from the US health regulator for Telmisartan Tablets, used for the treatment of hypertension, in the American market.
-
Jubilant Life Sciences Surges Over 50% In 7 Days. Read Why
Shares of Jubilant Life Sciences shares surged 15 per cent today to a fresh 52-week high of Rs 506, extending their strong run since the pharma company announced its June quarter earnings last week.
-
Jubilant Life Sciences Posts 22% Rise In Q1 Profit
Jubilant Life Sciences on Tuesday posted a 22.48 per cent rise in consolidated net profit at Rs 161.60 crore for the first quarter that ended on June 30, on robust sales in the pharmaceuticals segment.
-
India's Jubilant Signs Licensing Deal For US Pharma Firm Gilead's COVID-19 Drug
India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India.
-
Jubilant Life To Buy Triad Isotopes' Radio-Pharmacy Business, Shares Gain
Jubilant Life Sciences said Triad operates the second largest radio-pharmacy network in the US with more than 50 pharmacies.
-
Nearly 200 Stocks Hit 52-Week High On BSE
Among major gainers were IL&FS Transportation Networks, IOC, Jubilant Life Sciences, MMTC and MOIL, taking the total number of companies to have touched their one year peak to 192.
-
Jubilant Life Sciences Unit Signs US Deal, Shares Surge Over 10%
At day's high, Jubilant Life Sciences shares recorded gains of more than 13 per cent in two trading sessions.
-
Jubilant Life Sciences Announces Price Hike Of Up To 15%
Jubilant Life Sciences is engaged in pharmaceuticals, life science ingredients and drug discovery solutions.
-
Jubilant Life Seeks Shareholders' Nod To Raise Upto Rs 1,000 Crore
This approval to the board to raise the amount also stipulates that this could be done in one or more series/tranches during a period of one year from the date of passing the resolution, it added.
-
Jubilant Life Sciences Posts Nearly 15% Rise In Q2 Profit
Jubilant Life Sciences said its international revenues were at Rs 984 crore, contributing 69 per cent to the revenues for the quarter.
-
Jubilant Life Gets USFDA Nod For Urinary Incontinence Drug
Jubilant Life Sciences said it has received 6 approvals from the USFDA during the year.
-
Jubilant Life Sciences Arm Gets Australia TGA Nod For Lung Scan Drug
Jubilant Life Sciences on Tuesday said its wholly-owned subsidiary has received approval from the Australian health regulator Therapeutic Goods Administration (TGA) for Lyophilized kit for preparation of injection used for lungs scan.
-
Jubilant Life Shares Jump 10% As Arm Gets USFDA Nod For Drug
Shares of Jubilant Life Sciences on Monday surged 10 per cent after the company's wholly-owned subsidiary received approval from the US health regulator for a new drug in the US market.
-
Jubilant Pharma Raises $300 Million Via Bonds
Drug firm Jubilant Life Sciences today said its subsidiary Jubilant Pharma has raised $300 million (approx Rs 1,998 crore) through issuance of five-year bonds to mainly retire debts.
-
Jubilant Life Jumps 8% On USFDA Nod For Hypertension Tablets
Jubilant Life Sciences stock surged nearly 8 per cent after it received final approval from the US health regulator to sell tablets used in the treatment of hypertension in the American market.
-
Jubilant Life Gets USFDA Nod For Hypertension Tablets
Jubilant Life Sciences said it has received approval from the US health regulator for Telmisartan Tablets, used for the treatment of hypertension, in the American market.
-
Jubilant Life Sciences Surges Over 50% In 7 Days. Read Why
Shares of Jubilant Life Sciences shares surged 15 per cent today to a fresh 52-week high of Rs 506, extending their strong run since the pharma company announced its June quarter earnings last week.
-
Jubilant Life Sciences Posts 22% Rise In Q1 Profit
Jubilant Life Sciences on Tuesday posted a 22.48 per cent rise in consolidated net profit at Rs 161.60 crore for the first quarter that ended on June 30, on robust sales in the pharmaceuticals segment.
